What it's for (Indications)
- Cefprozil is a broad-spectrum, second-generation cephalosporin antibiotic indicated for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms.
- Its primary therapeutic applications encompass a range of bacterial infections, including those affecting the upper and lower respiratory tracts, skin and skin structures, and the middle ear.
- Specifically, it is utilized for pharyngitis/tonsillitis caused by *Streptococcus pyogenes*, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and secondary bacterial infections of acute bronchitis.
- Furthermore, cefprozil is effective in treating uncomplicated skin and skin structure infections, such as impetigo, as well as acute otitis media.
- The selection of cefprozil should always be based on susceptibility testing and local epidemiological patterns of resistance.
- Its efficacy has been well-established in both adult and pediatric populations for these specific indications, making it a valuable agent in managing common community-acquired bacterial infections.
- Adherence to diagnostic guidelines and susceptibility data is crucial for optimal therapeutic outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of cefprozil varies significantly based on the patient's age, the specific infection being treated, and renal function. For adults and adolescents (13 years and older) with pharyngitis/tonsillitis or acute bacterial sinusitis, a common regimen is 500 mg orally once daily for 10 days. For acute bacterial exacerbations of chronic bronchitis or secondary bacterial infections of acute bronchitis, the dosage is typically 500 mg orally once daily for 10 days. Uncomplicated skin and skin structure infections in adults are often treated with 250 mg or 500 mg orally once daily for 10 days, depending on severity. In pediatric patients (6 months to 12 years of age), for acute otitis media, the recommended dose is 15 mg/kg orally every 12 hours for 10 days, not exceeding the adult dose. For pharyngitis/tonsillitis, 7.5 mg/kg orally once daily for 10 days is typical, not exceeding the adult dose. Dosage adjustments are mandatory in patients with impaired renal function (creatinine clearance ≤ 30 mL/min), where the dose should be reduced by 50%. It is crucial to complete the full course of therapy, even if symptoms improve, to prevent the development of resistant bacteria and ensure eradication of the pathogen. |
Safety & Warnings
Common Side Effects
- Cefprozil is generally well-tolerated, but like all medications, it can cause adverse effects, ranging from mild to severe.
- The most frequently reported side effects are gastrointestinal in nature, including diarrhea (occurring in approximately 2-3% of patients), nausea, vomiting, and abdominal pain.
- Headaches and dizziness are also common central nervous system adverse events.
- Dermatological reactions, such as rash and urticaria, have been observed.
- Other less common but notable side effects include elevated liver enzymes (AST, ALT, alkaline phosphatase), eosinophilia, leukopenia, and superinfections, particularly candidiasis (vaginal and oral thrush).
- Serious but rare adverse events include severe hypersensitivity reactions (anaphylaxis), *Clostridioides difficile*-associated diarrhea (CDAD), angioedema, and erythema multiforme.
- Patients should be advised to seek immediate medical attention if they experience severe allergic reactions, persistent severe diarrhea, or signs of liver dysfunction such as jaundice.
- Monitoring for these adverse effects is important throughout the treatment course to ensure patient safety and prompt intervention.
Serious Warnings
- Black Box Warning: Cefprozil does not carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients should be acutely aware of several serious potential adverse effects and warnings associated with its use, which, while not warranting a black box, are of significant clinical importance and require careful consideration. ***Serious Warnings***: 1. **Hypersensitivity Reactions**: Serious, and occasionally fatal, hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam antibiotics, including cefprozil. These reactions are more likely to occur in individuals with a history of hypersensitivity to multiple allergens. Before initiating therapy with cefprozil, careful inquiry should be made concerning previous hypersensitivity reactions to cefprozil, cephalosporins, penicillins, or other drugs. If an allergic reaction to cefprozil occurs, the drug should be discontinued immediately, and appropriate medical therapy (e.g., epinephrine, corticosteroids, antihistamines) and supportive measures (e.g., oxygen, intravenous fluids, airway management) should be instituted as clinically indicated. 2. **Clostridioides difficile-Associated Diarrhea (CDAD)**: *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including cefprozil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*. Therefore, it is crucial to consider the diagnosis of CDAD in patients who present with diarrhea subsequent to the administration of any antibacterial agent. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment directed against *C. difficile*, and surgical evaluation should be instituted as clinically indicated. Diagnosis should be confirmed by laboratory testing. 3. **Superinfection**: The prolonged use of cefprozil, like other antibiotics, may result in the overgrowth of non-susceptible organisms, including fungi and other bacteria. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken, which may include discontinuing cefprozil and initiating alternative therapy.
- Careful consideration and clinical judgment are required when prescribing cefprozil due to several important warnings.
- Before initiating therapy, thorough inquiry should be made concerning previous hypersensitivity reactions to cefprozil, other cephalosporins, penicillins, or other drugs.
- Serious acute hypersensitivity reactions, including anaphylaxis, have been reported.
- If an allergic reaction to cefprozil occurs, the drug should be discontinued immediately, and appropriate medical therapy initiated, including supportive measures as needed.
- *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with nearly all antibacterial agents, including cefprozil, and may range in severity from mild diarrhea to fatal colitis.
- It is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.
- Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C.
- difficile*.
- Additionally, prolonged use of cefprozil may result in the overgrowth of non-susceptible organisms, necessitating careful monitoring for signs of superinfection during therapy, such as new or worsening fungal infections.
- Dosage adjustments are necessary in patients with significant renal impairment (creatinine clearance ≤ 30 mL/min) to prevent drug accumulation and potential toxicity.
How it Works (Mechanism of Action)
Cefprozil exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. As a beta-lactam antibiotic, it interferes with the third and final stage of bacterial cell wall assembly. Specifically, cefprozil binds to and inactivates penicillin-binding proteins (PBPs), which are enzymes located on the bacterial cytoplasmic membrane. These PBPs are crucial for catalyzing the transpeptidation reaction, a process that cross-links peptidoglycan chains, providing structural rigidity to the bacterial cell wall. By binding to PBPs, cefprozil prevents the formation of these cross-links, leading to a defective and weakened cell wall. The weakened cell wall can no longer withstand the osmotic pressure differences between the bacterial cytoplasm and the external environment, resulting in cell lysis and death. This mechanism of action is characteristic of all beta-lactam antibiotics. Cefprozil is active against a wide range of gram-positive and gram-negative bacteria, though its spectrum of activity is more directed towards gram-positive organisms compared to some later-generation cephalosporins, providing effective coverage for its indicated infections.